Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer.
The last earnings update was 34 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Oncolytics Biotech is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Oncolytics Biotech has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Oncolytics Biotech. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Oncolytics Biotech's earnings available for a low price, and how does
this compare to other companies in the same industry?
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Oncolytics Biotech's regulatory filings and announcements.
Oncolytics Biotech's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Oncolytics Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Oncolytics Biotech's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Oncolytics Biotech's finances.
The net worth of a company is the difference between its assets and liabilities.
Oncolytics Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Oncolytics Biotech's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Oncolytics Biotech's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Oncolytics Biotech has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Matthew C. Coffey, also known as Matt, Ph.D.,M.B.A., Co-founded Oncolytics Biotech Inc., and has been its Chief Executive Officer and President since January 19, 2017. Dr. Coffey served as Interim Chief Executive Officer and President of Oncolytics Biotech since November 2, 2016 until January 19, 2017. Dr. Coffey served as the Chief Operating Officer of Oncolytics Biotech Inc. since December 2008 until November 2016. He served as Vice President of Product Development from July 1999 to December 2004 and Chief Financial Officer of Oncolytics Biotech Inc., from September 1999 to May 2000 and Project Manager of SYNSORB from March 1999 to July 1999. He served as the Chief Scientific Officer of Oncolytics Biotech Inc., from December 9, 2004 to December 2008. He serves as a Scientific Advisor of Diamond International Group Inc. Dr. Coffey serves as an Independent Medical & Scientific Advisor of Amma Corporation. He has been a Director of Oncolytics Biotech Inc. since May 11, 2011. Dr. Coffey completed his Doctorate Degree in Oncology at the University of Calgary with a focus on the Oncolytics capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal.
Matt's compensation has been consistent with company performance over the past year, both up more than 20%.
Matt's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Oncolytics Biotech management team is about average.
Chief Financial Officer
Vice President of Investor Relations & Corporate Communications
Andrew de Guttadauro
Global Head of Business Development & President of Oncolytics Biotech (U.S.) Inc
Chief Medical Officer
Scientist of Translational Medicine
Dan Von Hoff
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Oncolytics Biotech board of directors is about average.
Board of Directors
Independent Chairman of the Board
Member of Scientific Advisory Board
Member of Scientific Advisory Board
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Oncolytics Biotech individual insiders in the past 3 months, but not in substantial volumes.
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer. It has collaboration with PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.